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Objectives. To determine the numbers of patients with peripheral vascular disease prescribed secondary prevention agents
following a lower limb amputation.
Design. A retrospective cross sectional study.
Methods. The clinical documentation of 107 vascular amputees (mean age 69.5, 2:1 male:female ratio) referred for pros-
thesis provision in 2004 and 2005 were analysed to determine levels of prescribing of anti-platelet agents, anti-coagulants
and cholesterol lowering drugs.
Results. Analysis of vascular amputees referred in 2004 and 2005 reveals that 41% were prescribed a statin and 39% were
prescribed a statin and 60% an anti-platelet agent. While 39% of these patients were on both drugs, 32% had been pre-
scribed neither.
Conclusions. The medical management of patients with severe peripheral vascular disease, even where their disease has led
to an amputation, is sub-optimal.
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Peripheral vascular disease (PVD) is the most com-
mon cause of lower limb amputation in the UK. In
2003e2004 there were over 3000 amputations carried
out for arteriosclerosis, representing 66% of all lower
limb amputations performed in this period.1 Arterial
disease is the most common reason for referral follow-
ing a lower limb amputation, accounting for 75 per
cent of all lower limb referrals. Diabetes currently
accounts for 42 per cent of these referrals. The number
of referrals where diabetes is recorded as the cause
of amputation has risen significantly over the last
8 years.1
The amputation of a lower limb in a patient with
PVD represents a ‘‘terminal’’ event, and is indicative
of severe arteriosclerosis, which may well also be pres-
ent in the coronary or cerebral arteries.2 Indeed, indi-
viduals with PVD are at a significantly higher risk of
having cerebrovascular disease or coronary heart dis-
ease.3,4 In one study, the 5 year survival rate following
a single lower limb amputation was only 33%.5
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in the secondary prevention of coronary artery dis-
ease6 and ischaemic stroke.7 There is less evidence
available for their effectiveness in the management
of PVD.8 Statin use has been shown to be effective
in the functional management of PVD independently
of serum lipid profiles.9 The administration of statins
to patients with PVD has also been shown to reduce
subsequent cardiovascular events,10 although this
effect is only seen in patients with high serum in-
flammatory markers. A further study has shown a re-
duction in cardiovascular events in a patient group
prescribed a statin following vascular surgery.11 An
assessment of patients with PVD undergoing vascular
bypass surgery demonstrated that subsequent graft
patency was increased and the risks of proceeding
to same limb amputation were decreased by the ad-
ministration of statins.12 The patency of autologous
infrainguinal bypass grafts is improved by the use
of statin therapy in the post operative period.13
Anti-platelet agents (clopidogrel, aspirin, dipyrida-
mole) have also been shown to reduce mortality from
stroke and cardiovascular disease in patients with
PVD.14 A large study looking at primary prevention of
cardiovascular events demonstrated that low dose aspi-
rin reduces the progression of intermittent claudication
and the risk of peripheral arterial surgery.15 The rolerved.
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tion of vascular disease in patients with PVD has been
evaluated in the CAPRIE trial16 which demonstrated
a relative risk reduction of 23.8% from death from MI
or stroke in patients with peripheral vascular disease
taking clopidogrel compared to aspirin. It is also known
that patients who receive anti-platelet therapy after re-
vascularisation procedures, whether this involves an-
gioplasty17 or bypass grafting18 have better primary
outcomes, in terms of longer termpatency rates thanpa-
tients who do not receive these treatments.
Unfortunately, there is a large degree of variability
in prescribing practice for the prevention of ischaemic
arterial disease in patients with PVD, as demonstrated
by an American study which looked at responses
to clinical scenarios amongst different prescribing
groups.19 There is evidence from some populations
that following a single lower limb amputation, there
is no significant increase in statin prescription.20 A
large multi-centre UK trial comparing bypass surgery
and balloon angioplasty for lower limb PVD21 found
that only a third of patients with severe lower ischae-
mia were on a statin and a third had not been pre-
scribed an antiplatelet agent.
Methods and Materials
A retrospective review of referral documentation to
a tertiary referral prosthetic centre during 2004 and
2005 clinic for amputees with PVD was conducted.
There were 107 patients in total (72 male and 35 fe-
male) with a mean age of 69.5. The date of amputation,
diabetic status, and drug regime were documented for
each patient and the results subsequently collated and
analysed for level of prescribing of anti-platelet agents
and statins. The patients in this study had their ampu-
tation performed at one of three local hospitals within
the catchment area for the limb fitting centre. Local
referral protocols meant that all patients who had
had an amputation and were medically well enough
to be discharged from hospital were seen, regardless
of age or medical co-morbidity.
Results
Analysis of all available documentation from 2004/
2005 reveals that only 47% of amputees had been pre-
scribed a statin by the time of referral to the prosthetic
clinic and 60% were on an anti-platelet agent (includ-
ing 7% who were taking warfarin). Only 39% of all
patients were on both and 32% had been prescribed
neither. The relative proportions of vascular amputees
on different types of secondary prevention are shownEur J Vasc Endovasc Surg Vol 32, November 2006(Table 1). The mean ages of the patient groups on both
treatments, a single treatment (statin or antiplatelet
agent) and no treatment were 71, 67 and 70 respec-
tively (total range 38e90). Sex ratios for each group
were approximately the same.
The percentage of patients on both statin and anti-
platelet drug was higher among non-diabetics (48%)
than diabetics (29%), while a greater proportion of
patients with diabetes were on neither treatment
(34%) compared with non-diabetics (27%) (Table 1).
Discussion
The findings of this small study correlate with those of
the BASIL trial21 and are probably representative of
most of the country as regards the medical manage-
ment of PVD. There is no difference in prescribing
patterns across different age and sex groups.
Given that vascular limb amputees represent the se-
vere end of the PVD spectrum, it is of some concern that
only a small proportion of these patients are receiving
optimal medical management in terms of the attenua-
tion of risk of more general atherosclerotic processes.
While the loss of one limb following an amputation
is a life changing event with social, economic and
emotional consequences to the patient and those
around him, the subsequent loss of a second limb
makes independent living and mobility much more
difficult.22 There are clearly compelling reasons above
and beyond secondary prevention of cerebrovascular
and cardiovascular disease for the aggressive medical
management of lower limb amputees with PVD.
The early initiation of medical management in pa-
tients with PVD is important for a number of reasons.
The prescription of statins has been shown to improve
functional mobility (walking distance).23 At a patho-
physiological level, lipid lowering treatment has
been shown to reduce carotid and femoral artery
intimal thickening.24 Where patients have come to
require vascular surgery, the risks of peri-operative
mortality are significantly reduced if a statin has
been prescribed prior to the surgical procedure.25
For diabetic patients, the administration of the lipid
lowering therapy, fenofibrate, was shown to reduce
Table 1. The total numbers of vascular amputees referred in 2004e
2005 on secondary prevention
All patients Diabetic Non diabetic
Total 109 65 44
Statin only 11 (8%) 8 (12%) 3 (7%)
Antiplatelet or
anticoagulant only
24 (21%) 16 (25%) 8 (18%)
Both 41 (39%) 20 (29%) 21 (48%)
Neither 33 (32%) 21 (34%) 12 (27%)
493Secondary Prevention in Amputeesthe incidence of amputation in the trial population by
30% over 5 years.26
The difficulty in the early identification and treat-
ment of this group of patients may have arisen
because, unlike primary heart disease or stroke, there
are no dedicated groups of physicians who are in-
volved with the medical management of PVD. Many
of these patients with general atherosclerotic disease
may have previously encountered cardiologists,
diabetologists or stroke physicians depending on
their co-morbidities, who may be more traditionally
involved in secondary prevention. However, primary
care physicians may see this as being outside their re-
mit (the treatment of PVD is not included in the new
General Medical Services Contract), while vascular sur-
geonsmay be focussedmore on the active physical man-
agement of the presenting problem. There is no mention
of secondary prevention in the British Society of Rehabil-
itation Medicine guidelines for amputee rehabilitation.27
The secondary prevention of arteriosclerosis is im-
portant in patients with peripheral vascular disease.
For patients with severe disease (as evidenced by am-
putation) this is vital in salvaging the remaining limb
and preventing cardiovascular disease and stroke. At
the present time, the medical management of some of
these patients is suboptimal and consideration should
be given as to how this can best be addressed.
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